Sage changes primary endpoint in key study months after analysts fret about depression drug's durability

Max Gelman

Senior Editor

In its quest to deliver a new drug to treat major depressive disorder, Sage Therapeutics recently updated its Phase III study with a change analysts …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Sage changes primary endpoint in key study months after analysts fret about depression drug's durability

Max Gelman

Senior Editor

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

Sage changes pri­ma­ry end­point in key study months af­ter an­a­lysts fret about de­pres­sion drug's dura­bil­i­ty

Max Gelman

Senior Editor

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

Sage changes primary endpoint in key study months after analysts fret about depression drug's durability

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

BeiGene will rebrand to BeOne Medicines, dropping name's link to China roots

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?